Posted by Michael Wonder on 13 Jan 2025
GSK’s Shingrix new pre-filled syringe presentation accepted for review by US FDA
10 January 2025 - An FDA decision on the application is expected by 20 June 2025.
GSK today announced that the US FDA has accepted for review the regulatory application of a pre-filled syringe presentation of Shingrix (GSK’s recombinant zoster vaccine) for the prevention of shingles (herpes zoster).
